Alnylam presents new data on RNAi therapeutics at ASH

Alnylam Pharmaceuticals (NASDAQ:ALNY) has presented research from programs in the company’s Alnylam 5×15” product pipeline at the American Society of Hematology (ASH) annual meeting and exposition in San Diego. Research included pre-clinical data from ALN-APC, an RNAi therapeutic targeting protein C for the treatment of hemophilia, and ALN-HPN, an RNAi therapeutic targeting the hepcidin pathway [...]

Alnylam completes enrollment in Phase 2b study of RSV Infection

Alnylam Pharmaceuticals (NASDAQ:ALNY) has completed patient enrollment in its Phase 2b study with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. The Phase 2b trial was designed as a multi-center, randomized, double-blind, placebo-controlled study in RSV-infected lung transplant patients. The study is being conducted at 33 lung transplant centers in [...]

Alnylam presents positive preliminary data for ALN-TTR01

Alnylam Pharmaceuticals (NASDAQ: ALNY) has presented positive preliminary results at a medical conference in Japan from its Phase 1 clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis  (ATTR). Data from the study show that administration of ALN-TTR01 resulted in statistically significant reductions in serum TTR protein levels [...]

Alnylam and GSK in RNAi pact for vaccines

Alnylam Pharmaceuticals (NASDAQ:ALNY) has formed a collaboration with GlaxoSmithKline (NYSE:GSK) focused on Alnylam’s VaxiRNA technology for certain GSK vaccine products, including influenza. VaxiRNA is a new RNAi technology for the enhanced production of viruses used in the manufacture of vaccine products. GSK is the first company to form a collaboration accessing this new platform. The [...]

Rodman starts Alnylam at market outperform

Rodman & Renshaw has initiated coverage of one-time market darling Alnylam Pharmaceuticals (NASDAQ:ALNY) with a “market outperform, speculative risk” rating and 12-month price target of $12. The stock closed at $7.13 yesterday. “It is our view that the shares have been overly punished by investors and the pendulum of sentiment has swung so far that [...]

Alnylam begins RNAi study in severe hypercholesterolemia

Alnylam Pharmaceuticals (NASDAQ:ALNY) has initiated dosing in a Phase 1 clinical trial with ALN-PCS, an RNAi therapeutic, targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia. The study is aimed at evaluating the safety and tolerability of ALN-PCS in subjects with elevated low-density lipoprotein cholesterol, or bad LDL cholesterol. It [...]

In conversation with Michael King and Elemer Piros

Rodman & Renshaw’s 13th Annual Healthcare Conference last week was another roaring success. Held in conjunction with Rodman’s Annual Global Investment Conference, total attendees reached some 4,000, with 400 presenting companies from the healthcare, mining, energy, financial services and clean technology sectors, Israel and China. In this exclusive interview with BioTuesdays.com, two of Rodman’s managing [...]

Prescription for growth

We, at biotuesdays.com, attended Dundee Capital Markets’ second emerging growth conference last week, where over 20 technology, life sciences and industrial growth companies presented. Dundee specializes in early-stage growth, and to say that the one-day showcase was jammed full of investment ideas is a bit of understatement. Here’s a sampling of what we took away [...]

FDA clears Tekmira Phase 1 trial

Tekmira Pharmaceuticals (TSX:TKM) has been cleared by the FDA to begin a Phase 1 human trial of its TKM-PLK1 treatment for patients with advanced solid tumour cancers, who are not well served by current therapy. The trial is scheduled to start before the end of 2010. It is designed to evaluate the safety, tolerability and [...]

Tekmira partner starts human trials of ALN-TTR01

Alnylam Pharmaceuticals (NASDAQ:ALNY), one of Tekmira Pharmaceuticals‘ (TSX:TKM) partners, has initiated dosing in a Phase 1 clinical trial of its ALN-TTR01 product candidate in patients with transthyretin-mediated amyloidosis (ATTR), a disease that results in damage to the peripheral nerves and heart. ALN-TTR01 is a RNA-interference therapeutic that uses Tekmira’s lipid nanoparticle delivery technology, SNALP (stable [...]

Next Page »